Haematologica (May 2017)

Long-term observation reveals high-frequency engraftment of human acute myeloid leukemia in immunodeficient mice

  • Anna M. Paczulla,
  • Stephan Dirnhofer,
  • Martina Konantz,
  • Michael Medinger,
  • Helmut R. Salih,
  • Kathrin Rothfelder,
  • Dimitrios A. Tsakiris,
  • Jakob R. Passweg,
  • Pontus Lundberg,
  • Claudia Lengerke

DOI
https://doi.org/10.3324/haematol.2016.153528
Journal volume & issue
Vol. 102, no. 5

Abstract

Read online

Repopulation of immunodeficient mice remains the primary method for functional assessment of human acute myeloid leukemia. Published data report engraftment in ~40–66% of cases, mostly of intermediate- or poor-risk subtypes. Here we report that extending follow-up beyond the standard analysis endpoints of 10 to 16 weeks after transplantation permitted leukemic engraftment from nearly every case of xenotransplanted acute myeloid leukemia (18/19, ~95%). Xenogeneic leukemic cells showed conserved immune pheno-types and genetic signatures when compared to corresponding pre-transplant cells and, furthermore, were able to induce leukemia in re-transplantation assays. Importantly, bone marrow biopsies taken at standardized time points failed to detect leukemic cells in 11/18 of cases that later showed robust engraftment (61%, termed “long-latency engrafters”), indicating that leukemic cells can persist over months at undetectable levels without losing disease-initiating properties. Cells from favorable-risk leukemia subtypes required longer to become detectable in NOD/SCID/IL2Rγnull mice (27.5±9.4 weeks) than did cells from intermediate-risk (21.9±9.4 weeks, P